<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422084</url>
  </required_header>
  <id_info>
    <org_study_id>SP-C-005-06</org_study_id>
    <nct_id>NCT00422084</nct_id>
  </id_info>
  <brief_title>Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients</brief_title>
  <official_title>A Phase III Comparative (Double-blind, Double-dummy) Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Coartem® (Artemether Lumefantrine) in Children &amp; Adult Patients With Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shin Poong Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <brief_summary>
    <textblock>
      The primary objective of this phase III study is to compare the efficacy and safety of the&#xD;
      fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of Coartem® (artemether&#xD;
      lumefantrine, AL) in children and adults with uncomplicated P falciparum malaria in Africa&#xD;
      and South East Asia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, comparative, randomised, (double-blind, double-dummy),&#xD;
      parallel-group, non-inferiority study comparing the efficacy and safety of the fixed&#xD;
      combination of PA with that of AL in the treatment of acute, uncomplicated P. falciparum&#xD;
      malaria. The study population will include 1269 patients, comprising male and female children&#xD;
      (≥20 kg body weight) and adults recruited from study sites in Africa and South East Asia.&#xD;
&#xD;
      Patients will be randomised to receive either oral PA (180:60mg tablets) once a day plus&#xD;
      AL-placebo (twice a day) for 3 consecutive days (Days 0, 1, and 2) or AL twice a day plus&#xD;
      PA-placebo (once a day) for 3 consecutive days (Days 0, 1, and 2) in a 2:1 ratio. The dose&#xD;
      range of PA covered by this regimen is 7.2:2.4 mg/kg to 13.8:4.6 mg/kg, respectively, which&#xD;
      has been shown to be effective and safe in Phase I and II studies. Posology will be based on&#xD;
      body weight ranges for both the PA and AL regimens.&#xD;
&#xD;
      Patients will be confined to the study facility for ≥4 days (Days 0, 1, 2, and 3) and remain&#xD;
      near the study site for ≥7 days, or once fever and parasite clearance has been confirmed for&#xD;
      ≥24 hours - whichever occurs later.&#xD;
&#xD;
      The primary efficacy end point for the study is the proportion of patients with PCR-corrected&#xD;
      adequate clinical and parasitological response (ACPR) on Day 28. Scheduled follow-up visits&#xD;
      will continue until completion of the study at Day 42. In the case of adverse events reported&#xD;
      and unresolved at Day 42, patients will be followed up for a further 30 days, or until&#xD;
      resolution of the event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28</measure>
    <time_frame>Day 14 and 28</time_frame>
    <description>Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 28, without correction by PCR, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time</measure>
    <time_frame>Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned)</time_frame>
    <description>Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time</measure>
    <time_frame>Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit and as clinically indicated</time_frame>
    <description>Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Fever Clearance at Day 1, 2 and 3</measure>
    <time_frame>Days 1, 2, 3</time_frame>
    <description>Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Parasite Clearance at Day 1, 2 and 3</measure>
    <time_frame>Days 1, 2, 3</time_frame>
    <description>Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Clinically Significant Laboratory Results</measure>
    <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
    <description>Incidence of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1272</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>PA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pyronaridine artesunate (PA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arthemether lumefantrine (AL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine artesunate</intervention_name>
    <description>Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
    <arm_group_label>PA group</arm_group_label>
    <other_name>Pyramax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coartem® (artemether lumefantrine)</intervention_name>
    <description>AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
    <arm_group_label>AL group</arm_group_label>
    <other_name>Coartem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between the age of 3 and 60 years, inclusive.&#xD;
&#xD;
          -  Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.&#xD;
&#xD;
          -  Presence of acute uncomplicated P. falciparum mono-infection confirmed by:&#xD;
&#xD;
               1. Fever, as defined by axillary/tympanic temperature ≥ 37.5°C or oral/rectal&#xD;
                  temperature ≥ 38°C, or documented history of fever in the previous 24 hours and,&#xD;
&#xD;
               2. Positive microscopy of P. falciparum with parasite density between 1,000 and&#xD;
                  100,000 asexual parasite count/μl of blood.&#xD;
&#xD;
          -  Written informed consent, in accordance with local practice, provided by patient&#xD;
             and/or parent/guardian/spouse.&#xD;
&#xD;
          -  Ability to swallow oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with signs and symptoms of severe/complicated malaria requiring parenteral&#xD;
             treatment according to the World Health Organization Criteria 2000.&#xD;
&#xD;
          -  Mixed Plasmodium infection.&#xD;
&#xD;
          -  Severe vomiting or severe diarrhoea.&#xD;
&#xD;
          -  Known history or evidence of clinically significant disorders.&#xD;
&#xD;
          -  Presence of significant anaemia, as defined by Hb &lt;8 g/dL.&#xD;
&#xD;
          -  Presence of febrile conditions caused by diseases other than malaria.&#xD;
&#xD;
          -  Known history of hypersensitivity, allergic or adverse reactions to pyronaridine,&#xD;
             lumefantrine or artesunate or other artemisinins.&#xD;
&#xD;
          -  Patients with known disturbances of electrolytes balance, e.g., hypokalaemia or&#xD;
             hypomagnesaemia.&#xD;
&#xD;
          -  Use of any other antimalarial agent within 2 weeks prior to start of the study as&#xD;
             evidenced by a positive urine test.&#xD;
&#xD;
          -  Female patients of child-bearing potential must be neither pregnant (as demonstrated&#xD;
             by a negative pregnancy test) nor lactating, and must be willing to take measures to&#xD;
             not become pregnant during the study period.&#xD;
&#xD;
          -  Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6&#xD;
             (flecainide, metoprol, imipramine, amitriptyline, clomipramine).&#xD;
&#xD;
          -  Received an investigational drug within the past 4 weeks.&#xD;
&#xD;
          -  Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen. (HBsAg) or&#xD;
             Hepatitis C antibody (HCV Ab).&#xD;
&#xD;
          -  Known seropositive HIV antibody.&#xD;
&#xD;
          -  Liver function tests [ASAT/ALAT levels] &gt;2.5 times the upper limit of normal range.&#xD;
&#xD;
          -  Known significant renal impairment as indicated by serum creatinine &gt;1.4 mg/dL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Oeuvray, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medicines for Malaria Venture</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ecole de Santé Publique, Faculté de Médecine, Université de Kinshasa</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farafenni Field Station, c/o: MRC Laboratories</name>
      <address>
        <city>Fajara</city>
        <country>Gambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komfo Anoykye Teaching Hospital</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RSUD TC Hillers</name>
      <address>
        <city>Maumere</city>
        <state>Nusa Tenggara Timur</state>
        <zip>86113</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jayapura General Hospital (RSUD) DOK II</name>
      <address>
        <city>Jayapura</city>
        <state>Papua</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siaya District Hospital, Medical Superintendent's office</name>
      <address>
        <city>Siaya</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malaria Research and Training Center, Faculté de Médecine, de Pharmacie et d'Ondonto-stomatologie</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Saude, Ministero de Saude</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Princesa General Hospital</name>
      <address>
        <city>Puerto Princesa</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Parasitologie, Faculté de Médecine, Université Cheikh Anta Diop</name>
      <address>
        <city>Dakar</city>
        <state>Dakar Fann</state>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
    <country>Gambia</country>
    <country>Ghana</country>
    <country>Indonesia</country>
    <country>Kenya</country>
    <country>Mali</country>
    <country>Mozambique</country>
    <country>Philippines</country>
    <country>Senegal</country>
  </location_countries>
  <removed_countries>
    <country>Congo</country>
  </removed_countries>
  <link>
    <url>http://www.mmv.org</url>
    <description>Medicines for Malaria Venture</description>
  </link>
  <results_reference>
    <citation>Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L; Pyronaridine-artesunate Study Team. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010 Apr 24;375(9724):1457-67. doi: 10.1016/S0140-6736(10)60322-4.</citation>
    <PMID>20417857</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <results_first_submitted>August 20, 2021</results_first_submitted>
  <results_first_submitted_qc>August 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2021</results_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>antimalarial</keyword>
  <keyword>artemisinin based combination therapy (ACT)</keyword>
  <keyword>P. falciparum</keyword>
  <keyword>pyronaridine artesunate (Pyramax)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
    <mesh_term>Pyronaridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PA Group</title>
          <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
        </group>
        <group group_id="P2">
          <title>AL Group</title>
          <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="849"/>
                <participants group_id="P2" count="423"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="751"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>P. vivax infection</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cyesis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn from study accidentally</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Re-location</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not defined</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population, defined as all randomized subjects who received any amount of study medication. Subjects were analyzed as randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>PA Group</title>
          <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
        </group>
        <group group_id="B2">
          <title>AL Group</title>
          <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="849"/>
            <count group_id="B2" value="423"/>
            <count group_id="B3" value="1272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.2" spread="11.12"/>
                    <measurement group_id="B2" value="18.0" spread="11.41"/>
                    <measurement group_id="B3" value="17.5" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="551"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="490"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="722"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="1080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mozambique</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gambia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mali</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Senegal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congo, The Democratic Republic of the</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ghana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indonesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28</title>
        <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
        <time_frame>Day 28</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PA Group</title>
            <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
          <group group_id="O2">
            <title>AL Group</title>
            <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28</title>
          <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
          <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="98.7" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.2" lower_limit="97.7" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The PCR-corrected ACPR response rate at Day 28 for the PA group is inferior to the PCR-corrected ACPR response rate at Day 28 for the comparator group (AL) by more than 5%.&#xD;
Was tested versus the alternative:&#xD;
Alternative hypothesis: The PCR-corrected ACPR response rate at Day 28 for the PA group is not inferior to the PCR-corrected ACPR response rate at Day 28 for the comparator group (AL) by more than -5%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The primary efficacy analysis tested the non-inferiority of the PA group compared to the comparator group with regard to the PCR-corrected ACPR response rate at Day 28 using the 2-sided 95% confidence interval (CI) (Newcombe-Wilson score method without continuity correction) and a 5% non-inferiority margin. Non-inferiority was demonstrated if the lower limit of the CI for the difference &gt;-5%.</non_inferiority_desc>
            <p_value>0.578</p_value>
            <p_value_desc>If non-inferiority of PA is demonstrated, the p-value associated with a superiority test was calculated based on a 2-sided Chi-square test. If the calculated p-value is &lt;5%, then the superiority of PA compared to AL is statistically demonstrated.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>ACPR percent difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14</title>
        <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
        <time_frame>Day 14</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PA Group</title>
            <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
          <group group_id="O2">
            <title>AL Group</title>
            <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14</title>
          <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
          <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="99.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28</title>
        <description>Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 28, without correction by PCR, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
        <time_frame>Day 14 and 28</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PA Group</title>
            <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
          <group group_id="O2">
            <title>AL Group</title>
            <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28</title>
          <description>Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 28, without correction by PCR, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
          <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure rate (%) at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="99.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cure rate (%) at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="97.8" upper_limit="99.5"/>
                    <measurement group_id="O2" value="97.2" lower_limit="95.0" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Time</title>
        <description>Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
        <time_frame>Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned)</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PA Group</title>
            <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
          <group group_id="O2">
            <title>AL Group</title>
            <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Time</title>
          <description>Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
          <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="23.9" upper_limit="23.9"/>
                    <measurement group_id="O2" value="24.0" lower_limit="23.9" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Clearance Time</title>
        <description>Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart</description>
        <time_frame>Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit and as clinically indicated</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PA Group</title>
            <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
          <group group_id="O2">
            <title>AL Group</title>
            <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Clearance Time</title>
          <description>Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart</description>
          <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="584"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="7.9" upper_limit="8.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="7.9" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Fever Clearance at Day 1, 2 and 3</title>
        <description>Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.</description>
        <time_frame>Days 1, 2, 3</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PA Group</title>
            <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
          <group group_id="O2">
            <title>AL Group</title>
            <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Fever Clearance at Day 1, 2 and 3</title>
          <description>Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.</description>
          <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="584"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clearance rate (%) at Day 1 (24h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="86.0" upper_limit="91.1"/>
                    <measurement group_id="O2" value="87.0" lower_limit="82.9" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 2 (48h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="97.9" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.7" lower_limit="96.8" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 3 (72h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="98.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.3" lower_limit="97.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Parasite Clearance at Day 1, 2 and 3</title>
        <description>Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
        <time_frame>Days 1, 2, 3</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PA Group</title>
            <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
          <group group_id="O2">
            <title>AL Group</title>
            <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Parasite Clearance at Day 1, 2 and 3</title>
          <description>Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
          <population>Efficacy evaluable population subjects completed a full course of study medication; has a known primary efficacy endpoint at D28; did not miss a dose due to vomiting (except at D0); did not use a concomitant medication (except acetaminophen); did not have a concomitant disease which may have interfered with the classification of the treatment outcome; and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clearance rate (%) at Day 1 (24h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="64.8" upper_limit="71.3"/>
                    <measurement group_id="O2" value="52.8" lower_limit="48.0" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 2 (48h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="96.9" upper_limit="98.9"/>
                    <measurement group_id="O2" value="97.2" lower_limit="95.1" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 3 (72h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="98.8" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events and Clinically Significant Laboratory Results</title>
        <description>Incidence of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities.</description>
        <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
        <population>The safety population consists of all randomized subjects who received any amount of study medication; subjects were analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>PA Group</title>
            <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
          <group group_id="O2">
            <title>AL Group</title>
            <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events and Clinically Significant Laboratory Results</title>
          <description>Incidence of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities.</description>
          <population>The safety population consists of all randomized subjects who received any amount of study medication; subjects were analyzed as treated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nr subj. with ≥1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509"/>
                    <measurement group_id="O2" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 treatment-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr pat with ≥1 treatment-related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 severe or life-threatening AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 AE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. ≥1 AE leading to drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 AE leading to study withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
      <desc>An AE was defined as any unfavorable and unintended sign, symptom, syndrome, or illness that developed or worsened during the period of observation in the clinical study.</desc>
      <group_list>
        <group group_id="E1">
          <title>PA Group</title>
          <description>Pyronaridine artesunate (PA)&#xD;
Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)</description>
        </group>
        <group group_id="E2">
          <title>AL Group</title>
          <description>Arthemether lumefantrine (AL)&#xD;
Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="849"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="849"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immunosuppression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="849"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="849"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="849"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="849"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="849"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="506" subjects_at_risk="849"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="849"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="849"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="849"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="41" subjects_at_risk="849"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="849"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="849"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="849"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="849"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="849"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="849"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="849"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="849"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="43" subjects_affected="42" subjects_at_risk="849"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="849"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="849"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Helminthic infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="849"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="849"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="849"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="849"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="849"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="849"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Upper respiratoty tract infection</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="849"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="849"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="849"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="849"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="849"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="849"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="849"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="76" subjects_affected="71" subjects_at_risk="849"/>
                <counts group_id="E2" events="42" subjects_affected="41" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="849"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="52" subjects_affected="49" subjects_at_risk="849"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephan Duparc, MD, Chief Medical Officer</name_or_title>
      <organization>Medicines for Malaria Venture (MMV)</organization>
      <phone>+41 22 555 0300 ext 351</phone>
      <email>duparcs@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

